Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DNV 3

Next Previous
Drug Profile

DNV 3

Alternative Names: DNV-3

Latest Information Update: 18 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhejiang Shimai Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Lymphoma; Malignant melanoma; Solid tumours
  • Discontinued Multiple sclerosis

Most Recent Events

  • 18 Sep 2025 DNV 3 is available for licensing as of 18 Sep 2025. https://www.centrymed.com/science-pip (Zhejiang Shimai Pharmaceutical pipeline, September 2025)
  • 18 Sep 2025 Discontinued - Phase-I for Multiple sclerosis in China (Parenteral) (Zhejiang Shimai Pharmaceutical pipeline, September 2025)
  • 18 Sep 2025 Phase-II clinical trials in Malignant melanoma (Combination therapy) (Parenteral), before September 2025 (Zhejiang Shimai Pharmaceutical pipeline, September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top